Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

doi:10.1200/JCO.2017.75.5009

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Jan 2018

Javle Milind, Lowery Maeve, Shroff Rachna T, Weiss Karl Heinz, Springfeld Christoph, Borad Mitesh J, Ramanathan Ramesh K, Goyal Lipika, Sadeghi Saeed, Macarulla Teresa, El-Khoueiry Anthony, Kelley Robin Kate, Borbath Ivan, Choo Su Pin, Oh Do-Youn, Philip Philip A, Chen Li-Tzong, Reungwetwattana Thanyanan, Van Cutsem Eric, Yeh Kun-Huei, Ciombor Kristen, Finn Richard S, Patel Anuradha, Sen Suman, Porter Dale, Isaacs Randi, Zhu Andrew X, Abou-Alfa Ghassan K, Bekaii-Saab Tanios

Abstract excerpt

Purpose No standard treatment exists for patients with cholangiocarcinoma for whom first-line gemcitabine-based therapy fails. Fibroblast growth factor receptor 2 ( FGFR2) fusions/translocations are present in 13% to 17% of intrahepatic cholangiocarcinomas. BGJ398, an orally bioavailable, selective pan-FGFR kinase inhibitor, has shown preliminary clinical activity against tumors with FGFR alterations. Methods A...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bile Duct Neoplasms

Share to Cholangiocarcinoma

Share to Drug Administration Schedule

Share to Gene Fusion

Share to Phenylurea Compounds

Share to Progression-Free Survival

Share to Receptor, Fibroblast Growth Factor, Type 2

Source

Open in PubMed Open full text

Identifiers

PMID: 29182496
DOI: 10.1200/JCO.2017.75.5009
PMCID: PMC6075847

Genes

FGFR2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.PMID 29182496Read ↗

Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma.Semantic proximity Read ↗

Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial.Semantic proximity Read ↗

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements.Semantic proximity Read ↗

FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.Semantic proximity Read ↗

Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications.Semantic proximity Read ↗

FGFR2 Inhibition in Cholangiocarcinoma.Semantic proximity Read ↗

Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.Semantic proximity Read ↗

A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors.Semantic proximity Read ↗

Biliary cancer: gateway to comprehensive molecular profiling.Semantic proximity Read ↗

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.Semantic proximity Read ↗

Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy.Semantic proximity Read ↗

Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.